Analysts Set Billiontoone, Inc. (NASDAQ:BLLN) Price Target at $129.57

Shares of Billiontoone, Inc. (NASDAQ:BLLN) have earned an average recommendation of “Moderate Buy” from the ten brokerages that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $129.5714.

A number of research analysts have commented on BLLN shares. Zacks Research raised Billiontoone to a “hold” rating in a report on Tuesday, December 2nd. Wall Street Zen upgraded Billiontoone from a “hold” rating to a “buy” rating in a report on Saturday, March 7th. Jefferies Financial Group started coverage on Billiontoone in a research note on Monday, December 1st. They set a “hold” rating and a $117.00 price objective on the stock. BTIG Research decreased their price objective on shares of Billiontoone from $160.00 to $140.00 and set a “buy” rating for the company in a report on Thursday, March 5th. Finally, William Blair initiated coverage on shares of Billiontoone in a research note on Monday, December 1st. They set an “outperform” rating for the company.

Billiontoone Stock Performance

Shares of Billiontoone stock opened at $69.76 on Wednesday. The company has a current ratio of 11.69, a quick ratio of 11.32 and a debt-to-equity ratio of 0.12. Billiontoone has a 1 year low of $61.96 and a 1 year high of $138.70. The firm has a 50-day moving average of $82.98. The firm has a market cap of $3.19 billion and a price-to-earnings ratio of 332.19.

Billiontoone (NASDAQ:BLLN) last posted its quarterly earnings results on Wednesday, March 4th. The company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.07. The firm had revenue of $96.05 million during the quarter, compared to analyst estimates of $85.85 million. The company’s revenue for the quarter was up 113.0% compared to the same quarter last year.

Institutional Investors Weigh In On Billiontoone

A number of institutional investors have recently modified their holdings of BLLN. Adams Street Partners LLC acquired a new stake in Billiontoone during the fourth quarter worth about $140,063,000. Baillie Gifford & Co. acquired a new position in Billiontoone in the fourth quarter valued at approximately $103,786,000. Price T Rowe Associates Inc. MD acquired a new position in Billiontoone in the fourth quarter valued at approximately $39,717,000. JPMorgan Chase & Co. bought a new position in shares of Billiontoone during the fourth quarter valued at approximately $32,078,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of Billiontoone during the 4th quarter worth approximately $18,631,000.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.